Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.
beta-blocking agents are now well established as a cornerstone therapy in mild to moderate heart failure. Patients with more advanced heart failure depend on adrenergic activation to maintain adequate myocardial function. This leads to significant difficulties in using beta-blockers in advanced or severe heart failure. In addition, recent data indicate that adrenergic withdrawal might be detrimental in some of these patients. In higher doses, positive inotropic agents have been shown to increase mortality when used alone in subsets with advanced heart failure. Preliminary data suggest that the combination of low-dose phosphodiesterase inhibitors and a beta-blocker may be better tolerated and does not appear to be associated with the adverse effects of either therapy used alone. We discuss the theoretic underpinning of this approach and the supportive clinical data.
Shakar
S F
SF
University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA.
Bristow
M R
MR
D000319:Adrenergic beta-Antagonists; D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D000075202:Contraindications; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D010726:Phosphodiesterase Inhibitors